SR33805 is a potent Ca 2+ channel antagonist, with EC 50 s of 4.1 nM and 33 nM in depolarized and polarized conditions, respectively. SR33805 blocks L-type but not T-type Ca 2+ channels. SR33805 can be used for the research of acute or chronic failing hearts In Vitro SR33805 (0.01-10 µM; 3 d) inhibits growth factor-induced proliferation of SMC (0.20 50 In Vivo SR33805 (20 mg/kg; a single i.p.) improves end-systolic strain and fractional shortening of MI hearts in rats. SR33805 (5 mg/kg/day; p.o. for 38 d) significantly reduces intimal hyperplasia in pigs. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male Wistar rats (5 weeks) are subjected to coronary artery ligatureDosage: 0.2, 2, 20 mg/kg Administration: A single i.p. injection Result: Increased significantly both end-systolic strain (ESS) and fractional shortening (FS) by about +38 and +26%, respectively at the dose of 20 mg/kg. Did not affect other contractile parameters. Form:Solid IC50& Target:L-type calcium channel 4.1 nM (EC 50 , in depolarized conditions) L-type calcium channel 33 nM (EC 50 , in polarized conditions)